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ABSTRACT  
Thiopurines bis(S-8-thiotheophylline)methane (MBTTH2), 1,2-bis(S-8-
thiotheophylline)ethane (EBTTH2) and 1,3-bis(S-8-thiotheophylline)propane 
(PBTTH2) were reacted with [RuClCp(mPTA)2](CF3SO3)2 in water to afford the bi-
ruthenium complexes [{RuCp(mPTA)2}2-µ-(L-kN7,N´7)](CF3SO3)4 (1: L = MBTT; 2:  L 
= EBTT; 3: L = PBTT), which have been characterized by elemental analysis, IR and 
NMR multinuclear (1H, 13C{1H}, 31P{1H} and 19F{1H}) spectroscopy. Diffusion 
experiments for 1 were carried out. Proposed structures for the three complexes 
were also supported by theoretical calculations. Their cyclic voltammetry showed that 
all these complexes are characterized by two one-electron irreversible oxidative 
responses (RuII–RuII/RuIII–RuII; RuIII–RuII/RuIII–RuIII). Complexes showed pour 
antiplorifelative activity against cisplatin-sensitive T2 human cell line and the 
cisplatin-resistant SKOV3 cell line. 
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1. Introduction 
The cisplatin is one of the most widely used drugs for treatment of cancer 
[1,2]. Despite of its wide applicability this drug displays high toxicity, producing 
severe side effects. Another important problem is the lack of general activity 
[3]. To overcome these problems many attempts have been done, being one 
of the most useful strategy to develop alternatives to platinum based drugs 
[4]. The ruthenium complexes have shown to be one of the most valuable 
candidates to substitute the platinum compounds. Ruthenium complexes use 
to be characterized by variable oxidation states, low toxicity, selectivity for 
cancer cells and ability to mimic iron in binding to biomolecules [5]. Two of the 
most promising ruthenium complexes as new anticancer drugs are the 
KP1019 and NAMI-A, which are in the last clinical evaluation stages [6]. 
Notably, these complexes exhibit a comparable to cisplatin antitumor 
properties but with lest toxicity and related side effects [3-5]. One of the 
valuable properties of the complexes to be a drug is their capacity of 
dissolving in water as the natural life is constituted mainly by this solvent. Our 
research team aimed the synthesis of new anticancer-active platinum and 
ruthenium complexes soluble in water, some of them with better activity than 
cisplatin [7]. Some of these complexes contain water-soluble phosphines such 
as PTA and its derivatives mPTA and dmPTA (PTA = 1,3,5-triaza-7-
phosphaadamantane; mPTA = N-methyl-1,3,5-triaza-7-phosphaadamantane; 
dmPTA = N,N′-dimethyl-1,3,5-triaza-7-phosphaadamantane) [8]. To obtain 
additional information on how the ruthenium complexes containing PTA and 
mPTA interact with purines their reactivity with thio- and bis-thio-theophyllines 
were evaluated. The thio-derivatives show interesting properties useful to 
obtain initial information on how the metal complexes could acts on the 
purines. They have only a limited number of coordination positions in contrast 
with DNA-purines as well as more solubility in organic solvents and groups 
active in 1H and 13C NMR. Bis-thiopurines are particularly interesting as they 
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bear two purines depending on the length of the spacing group. This 
disposition of the purines could mimic the DNA, providing easily interesting 
information that could be useful for understand how metal complexes could 
interact with DNA. In previous papers we have published the reactivity of 
water-soluble ruthenium(II) mononuclear complexes [RuClCp(PTA)(L)] with 
bis-thiotheophyllines (Figure 1) that provided binuclear complexes 
[{RuCp(PTA)(L)}2-μ-(Y-kS,S′)] (Y = MBTT2−, EBTT2−, PBTT2−; L = PTA, PPh3) 
[9]. The evaluation of the anticancer activity of these complexes against 
cisplatin-sensitive T2 and cisplatin-resistant SKOV3 cell lines showed that 
these complexes do not display significant antiproliferative activity. 
Complexes [{RuCp(PPh3)(mPTA)}2-μ-(Y-kS,S′)] showed that the combination 
of bispurines with ruthenium with mPTA, soluble in water, and PPh3, soluble 
in organic solvents, are non-reactive against DNA. Their low solubility in the 
standard dmso/water mixture avoided the evaluation of their antiproliferative 
activity against living cells [10]. Nevertheless, these complexes showed that 
their oxidation potentials are related with the purine linking group size. To 
determine if this behavior is reproducible and independent of the phosphine 
bonded to the metal and if a water soluble parent complexes display 
antiproliferative activity, three new water-soluble neutral binuclear ruthenium 
complexes [{RuCp(mPTA)2}2-μ-(Y-kS7,S′7)](CF3SO3)4 were synthesized and 
their redox properties studied, which are similar to those previously studied 
but in which the metal is bonded to two mPTA instead to one mPTA and one 
PPh3. 
 
 
 
 
 
 
Figure 1. Chemical structure of 8-bis-thiopurines 
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2. Experimental  
2.1. General procedures 
 
All reactions and manipulations were routinely performed under a dry 
nitrogen atmosphere by using standard Schlenk-tube techniques. All 
chemicals were reagent grade and were used as received by commercial 
suppliers unless otherwise stated. The solvents were all degassed and 
distilled according to standard procedures [11 ]. The compounds mPTA, 
[RuClCp(mPTA)2](CF3SO3)2 and bis(8-thiotheophylline) alkane derivatives 
MBTTH2, EBTTH2 and PBTTH2 were prepared following the procedure 
described in literature [12]. Solvents for NMR measurements (Cortec-Euriso-
top) were dried over molecular sieves (0.4 nm). 1H, 31P{1H} NMR and 13C{1H} 
NMR spectra were recorded on a Bruker DRX300 spectrometer operating at 
300.13 MHz (1H), 121.49 MHz (31P), 282.40 MHz (19F) and 75.47 MHz (13C), 
respectively. Peak positions are relative to tetramethylsilane and were 
calibrated against the residual solvent resonance (1H) or the deuterated 
solvent multiplet (13C). Chemical shifts for 31P{1H} NMR were measured 
relative to external 85% H3PO4, and for 19F{1H} NMR to CFCl3, they were 
measured with downfield values taken as positive in both cases. Infrared 
spectra were recorded on KBr discs using an FT-IR ATI Mattson Infinity 
Series. Elemental analysis (C, H, N, S) was performed on a Fisons 
Instruments EA1108 elemental analyser.  
 
 
2.2. Synthesis of [{RuCp(mPTA)2}2-µ-(MBTT-kS7,S´7)](CF3SO3)4 (1) 
The bis-thiopurine MBTTH2 (0.016 g, 0.036 mmol) was added into 10 
mL of an aqueous solution of KOH (0.0075 M) and the initial mixture stirred 
until complete dissolution of the ligand. When dissolved the complex 
[RuClCp(mPTA)2](CF3SO3)2 (0.055 mg, 0.065 mmol) was added and refluxed 
for 4 h. The resulting mixture was cooled, filtered and concentrated by 
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evaporation to 1 mL. The obtained precipitate was filtered, washed with EtOH 
(2x 2 mL), Et2O (2 x 2 mL) and vacuum dried. 
Yield powder: 0.057 g, 87%. S25 ºC,H2O(mg/mL): 30. Log P: -0.38. Elemental 
analysis for C57H84N20F12O16P4Ru2S6 (2051.81 g.mol-1): Found C, 33.42; H, 
4.18; N, 13.51; S, 9.23 %; calcd. C, 33.37; H, 4.13; N, 13.65; S, 9.38%. IR 
(KBr, cm-1): n(C2=O) 1681 (s); n(C6=O) 1635 (s); n(C=C+C=N) 1523 (s); 
n(SO) 1226 (s). 1H RMN (20 ºC, D2O): d 2.78 (s, CH3NmPTA, 12H); 3.26 (s, 
CH3N1MBTT, 6H); 3.47 (s, CH3N3MBTT, 6H); 3.71-3.98 (m, NCH2PmPTA, 24H); 
4.11-4.86 (m, NCH2NmPTA+ CH2SMBTT, 24H+2H); 5.02 (s, Cp, 10H). 13C{1H} 
RMN (20 ºC, DMSO-d6): d 16.69 (s, CH2SMBTT); 28.12 (s, CH3N1MBTT); 30.64 
(s, CH3N3MBTT); 49.21 (s, CH3NmPTA); 52.55 (d,1JCP = 51.80 Hz, NCH2PmPTA); 
60.57 (bd, 1JCP = 58.0 Hz, CH3NCH2PmPTA); 68.68 (s, NCH2NmPTA); 79.84 (s, 
CH3NCH2NmPTA); 84.23 (s, Cp); 114.63 (s, C5MBTT); 119.53 (q, 1JCP = 316.86 
Hz, OSO2CF3); 149.92 (s, C4MBTT); 153.32 (s, C8MBTT); 160.41 (s, C6MBTT);  
169.24 (s, C2MBTT). 31P{1H} RMN (20 ºC, D2O): d -7.85 (s, mPTA). 19F NMR 
(D2O): d -78.94 (s). Cyclic voltammetry (DMF, 22 °C): Eox = 0.706 V, 0.880 V.  
 
2.3. Synthesis of [{RuCp(mPTA)2}2-µ-(EBTT-kS7,S´7)](CF3SO3)4 (2) 
Complex 2 was synthesized by a similar method than that described 
previously for 1. The ligand EBTTH2 (12.35 mg, 0.026 mmol) was dissolved 
into 10 mL of an aqueous solution of KOH (0.0053 M) before adding 
[RuClCp(mPTA)2](CF3SO3)2 (42.00 mg, 0.050 mmol). The final product is 
yellow.  
Yield powder: 0.0325 g, 60%. S25 ºC,H2O(mg/mL): 12. Log P: -0.49. Elemental 
analysis for C58H86F12N20O16P4Ru2S6 (2056.84 g.mol-1): Found C, 33.76; H, 
4.28; N, 13.56; S, 9.22 %; calcd. C, 33.72; H, 4.20; N, 13.56; S, 9.31 %. IR 
(KBr, cm-1): n(C2=O) 1683 (s); n(C6=O) 1630 (s); n(C=C+C=N) 1521 (s). 1H 
RMN (20 ºC, D2O): d 2.75 (s, CH3NmPTA, 12H); 3.34 (s, CH3N1EBTT, 6H); 3.86 
(s, CH3N3EBTT, 6H); 3.81-4.93 (m, CH2SEBTT+NCH2PmPTA+ NCH2NmPTA, 
4H+24H+24H); 4.87 (s, Cp, 10H). 13C{1H} RMN (20 ºC, DMSO-d6): d 27.80 (s, 
CH3N1EBTT); 30.25 (s, CH3N3EBTT); 32.35 (s, CH2SEBTT); 48.58 (s, CH3NmPTA); 
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52.33 (d, 1JCP  = 50.78 Hz, NCH2PmPTA); 61.14 (bd, 1JCP = 58.0 Hz, 
CH3NCH2PmPTA); 68.77 (s, NCH2NmPTA); 78.10 (s, CH3NCH2NmPTA); 82.51 (s, 
Cp); 116.80 (s, C5EBTT); 118.87 (q, 1JCP = 316.85 Hz, OSO2CF3); 151.34 (s, 
C4EBTT); 151.78 (s, C8EBTT); 156.46 (s, C6EBTT); 157.64 (s, C2EBTT). 31P{1H} 
RMN (20 ºC, D2O): d -8.51 (s, mPTA). 19F NMR (D2O): d -78.91 (s). Cyclic 
voltammetry (DMF, 22 °C): Eox = 0.546 V, 0.826 V.  
 
2.4. Synthesis of [{RuCp(mPTA)2}2-µ-(PBTT-kS7,S´7)](CF3SO3)4 (3) 
Similarly to previous methods, the bis-thiopurine PBTTH2 (0.014 g, 
0.031 mmol) was dissolved in 10 mL of KOH in water (0.0067 M) and reacted 
with [RuClCp(mPTA)2](CF3SO3)2 (0.040 g, 0.054 mmol) at refluxing 
temperature to give finally a yellow powder. 
Yield powder: 0.0325 g, 58%. S25 ºC,H2O(mg/mL): 15.0. Log P: -0.55. Elemental 
analysis for C59H88F12N20O16P4Ru2S6 (2079.87 g.mol-1): Found. C, 34.07; H, 
4.34; N, 13.38; S, 9.13 %; calcd. C, 34.15; H, 4.26; N, 13.47; S, 9.25%. IR 
(KBr, cm-1): n(C2=O) 1682 (s); n(C6=O) 1634 (s); n(C=C+C=N) 1544 (s); 
n(SO) 1224 (s). 1H RMN (20 ºC, D2O): d 2.05 (q, CH2CH2SPBTT, 2H), 2.77 (s, 
CH3NmPTA, 12H); 3.18 (s, CH3N1PBTT, 6H); 3.32 (s, CH3N3PBTT, 6H); 3.45 (t, 
CH2SPBTT), 4H); 3.84-4.10 (m, NCH2PmPTA, 24H); 4.30-4.57 (m, NCH2NmPTA, 
24H); 4.88 (s, Cp, 10H). 13C{1H} RMN (20 ºC, DMSO-d6):d 28.08 (s, 
CH3N1PBTT); 29.73 (s, CH3N3PBTT); 30.05 (s, CH2CH2SPBTT); 30.51 (s, 
CH2SPBTT); 48.60 (s, CH3NmPTA); 51.68 (d, 1JCP= 50.80 Hz, NCH2PmPTA); 60.08 
(bd, 1JCP = 58.15 Hz, CH3NCH2PmPTA); 68,78 (s, NCH2NmPTA); 78.12 (s, 
CH3NCH2NmPTA); 81.76 (s, Cp); 118.82 (q, 1JCP  = 316.80 Hz, OSO2CF3); 
116.64 (s, C5PBTT); 151.24 (s, C4PBTT); 153.64 (s, C8PBTT); 158.75 (s, C6PBTT);  
166.00 (s, C2PBTT). 31P{1H} RMN (20 ºC, D2O): d -8.52 (s, mPTA). 19F NMR 
(D2O): d -78.95 (s). Cyclic voltammetry (DMF, 22 °C): Eox = 0.469 V, 0.813 V.  
 
2.5. Stability tests of the complexes with O2 and H2O 
 
The ruthenium complexes 1, 2 and 3 were air stable for months in the 
solid state and for two days in solution. In a general procedure, the complex 
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(0.01 g) was introduced into a 5 mm NMR tube and dissolved in 0.5 mL of 
D2O, the solution cooled at 4 ºC and then dry O2 bubbled for 2 min via a long 
syringe needle. 31P{1H} NMR showed that no significant changes were 
produced in two days at room temperature. No significant decomposition was 
observed after one days at 40 °C as well. Sequential additions of 50 μL of 
DMSO-d6 did not produce any significant change in the starting complexes 
after one days at 40 °C. 
 
 
2.6. Cyclic voltammetry experiments 
 
Electrochemical experiments were performed with a VersaSTAT3 
apparatus. A standard disposition for the measurement cell was used 
including a three-electrode glass cell consisting of a platinum disk-working 
electrode, a platinum-wire auxiliary electrode and an Ag reference electrode. 
The supporting electrolyte solution (LiClO4, 0.05 M) was scanned over the 
solvent window to verify the absence of electro-active impurities. A similar 
concentration of the analyte (0.1 mM) in H2O was employed in all the 
measurements. 
 
 
2.7. Octanol-Water Partition Coefficient Determination  
 
Accurate Log P values corresponding to the octanol-water partition 
coefficient [13] was adjusted to the solubility properties of the complexes. 
Complexes were dissolved in octanol previously saturated with distilled water 
with concentration range between 10-4 and 10-3 M. Into a 40 mL container at 
25±1 ºC with a magnetic stir bar was introduced initially 10 mL of water 
previously saturated with octanol and then by a syringe 10 mL of the complex 
solutions in octanol, one so that the solution did not emulsify. Samples were 
taken from the octanol and water phases with a syringe until complex 
concentration in both phases stabilized, which was measured by UV-vis 
spectroscopy. 
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2.8. Growth Inhibition Assays 
Cell growth inhibition assays were carried out using the cisplatin-
sensitive T2 human cell line and the cisplatin-resistant SKOV3 cell line. T2 is 
a cell hybrid obtained by the fusion of the human lynphoblastoid line 174 (B 
lynphocyte transformed by the Epstein-Barr virus) with the CEM human 
cancer line (leukaemia T) while SKOV3 is derived from a human ovarian 
tumour. The cells were seeded in triplicate in 96-well trays at a density of 
50·103 in 50 µl of AIM-V medium for T2, 25·103 in 50 µl of AIM-V medium for 
SKOV3. Stock solutions (10 mM) of the Ruthenium complexes 1-3 were made 
in DMSO and diluted in AIM-V medium to give final concentration of 2, 10 and 
50 µM. Cisplatin was employed as a control for the cisplatin-sensitive T2 cell 
line and for the cisplatin-resistant SKOV3. Untreated cells were placed in 
every plate as a negative control.  The cells were exposed to the compounds 
for 72 h and then 25 µl of a 4,5-dimethylthiozol-2-yl)2,5-diphenyltetrazolium 
bromide solution (12 mM) were added. After two hours of incubation, 100 µl of 
lysing buffer (50% DMF + 20% SDS, pH 4.7) were added to convert 4,5-
dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide into a brown coloured 
formazane. After additional 18 hours the solution absorbance, proportional to 
the number of live cells, was measured by spectrophotometer and converted 
in % of growth inhibition [14]. 
 
 
2.9. Calculation details 
 
DFT calculations at B3LYP [15] level geometry optimizations of 1 - 3 in 
vacuum were carried out using NWCHEM 6.3 software package [16]. A 
Gaussian basis set of 3-21g was used for the structure optimization.  
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3. Results and discussion 
 
3.1. Synthesis and characterization of 1–3 
 
The dinuclear ruthenium complexes 1, 2 and 3 were obtained by reaction 
respectively of MBTTH2, EBTTH2 and PBTTH2 with KOH and 2 equiv of 
RuClCp(mPTA)2](CF3SO3)2 in refluxing water (scheme 1). 
 
 
 
 
 
 
 
 
Scheme 1. Synthesis of 1, 2, and 3. 
 
The three complexes are yellow, soluble in water, DMSO and DMF but 
very low soluble in organic solvents. They are stable in solid state for months 
and in water for two days at room temperature and one day at 40 ºC also 
when DMSO-d6 was added. The additional mPTA ligand provides to the new 
bi-metallic complexes 1, 2 and 3 more water-solubility than those for the 
parent complexes [{RuCp(PPh3)(PTA)}2-μ-(Y-kS7,S′7)] [9], [{RuCp(PTA)2}2-μ-
(Y-kS7,S′7)] [9] and [{RuCp(PPh3)(mPTA)}2-μ-(L-kS7,S′7)] [10].  The 
elemental analyses of the complexes were in agreement with a proportion of 
two {CpRu(mPTA)2}2+ units to one bis-thiopurine molecule. The 31P{1H} NMR 
spectra for the three complexes show a singlet at -7.85 ppm (1), -8.51 ppm 
(2), and -8.52 (3). The 1H NMR (D2O) signals only could be assigned using 
1H,1H-2D COSY NMR, and by comparison with those for the parent previously 
published bimetallic Ru complexes: [{RuCp(PPh3)(PTA)}2-μ-(L-kS7,S′7)] [9] 
and [{RuCp(PTA)2}2-μ-(L-kS7,S′7)] [9] and [{RuCp(PPh3)(mPTA)}2-μ-(L-
kS7,S′7)] [10]. The resonances for N1CH3 and N3CH3 were observed 
indicating the presence of the purines [9,10]. The 1 S–CH2–S broad signal 
(4.50 ppm) is in the range found for the mPTA-CH2 signals, which is similar to 
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those found for [{RuCp(PPh3)(PTA)}2-μ-(L-kS7,S′7)] (4.62 ppm) [9], 
[{RuCp(PPh3)(mPTA)}2-μ-(L-kS7,S′7)] (4.68 ppm) [10] cis-[{PtCl(PPh3)2}2(μ-
MBTT-kN7,N7′)] (5.0 ppm) [22], cis-[{Pt(PTA)2}2(μ-Cl)(μ-MBTT-kN7,N7′)]Cl 
(4.21 ppm) [12a] and trans-[{PdCl(PPh3)2}2(μ-MBTT-kN7,N7′)] (4.15 ppm) 
[12b]. 
In the 1H NMR of 2 the four S(CH2)2S protons are chemically different 
and arise as multiplets in similar range that those found from 3.81 to 4.93 ppm 
that is somewhat shifted to low field than those found in similar ruthenium 
complexes containing this ligand, Cp, and PTA: [{RuCp(PPh3)(PTA)}2-μ-(L-
kS7,S′7)] (2.72 ppm to 3.62 ppm) [9], [{RuCp(PTA)2}2-μ-(L-kS7,S′7)] (3.17 to 
3.44 ppm) [9] and [{RuCp(PPh3)(mPTA)}2-μ-(L-kS7,S′7)] (2.86 to 3.10  ppm) 
[10]. In the few known EBTT2− complexes with other metals a broad singlet 
was observed for this group: trans-[{PdCl(PPh3)2}2(μ-EBTT-kN7,N′7)] (S-
(CH2)2-S = 2.87 ppm) [13c] and cis-[{Pt(PTA)2}2(μ-Cl)(μ-EBTT-kN7,N7′)]Cl (S-
(CH2)2-S = 1.92 ppm) [13c]. This fact suggests that the ligand EBTT− 
coordinates more through the closer sulfur, which are bonded to the –CH2–
CH2– group, than through the two distant imidazolic N7 atoms.  
The 1H NRM spectrum of 3 displays the Cp as a broad signal and the 
S-(CH2)3-S signals as multiplets at chemical shifts (-CH2- = 2.05 ppm; S-CH2- 
= 3.45 ppm) rather different to those for free PBTTH2 (-CH2- = 2.17 ppm; S-
CH2- = 3.40 ppm) and coordinated PBTT2− in complexes: 
[{RuCp(PPh3)(PTA)}2-μ-(L-kS7,S′7)] (-CH2- = 2.20 ppm;  S-CH2- = 3.22, 4.48 
ppm) [9], [{RuCp(PTA)2}2-μ-(L-kS7,S′7)] (-CH2- = 1.56 ppm; S-CH2- = 2.95, 
4.46 ppm) [9], [{RuCp(PPh3)(mPTA)}2-μ-(L-kS7,S′7)] (-CH2-  = 2.08 ppm; S-
CH2- = 3.37 ppm) [10], cis-[{Pt(PTA)2}2(μ-Cl)(μ-PBTT-κN7,N′7)]Cl (-CH2- = 
2.03 ppm; S-CH2- = 3.39 ppm) [13] and trans-[{PdCl(PPh3)2}2(μ-PBTT-
kN7,N′7)] (-CH2-  = 2.56 ppm; S-CH2- = 3.72 ppm) [13c]. This result supports 
newly that sulfurs are the probable coordination point of PBTT− in 3.  
The 13C{1H} NMR spectrum of 1 shows the SCH2S and C8 signals (S-
CH2-S = 36.21 ppm; C8 = 153.32 ppm) with a chemical shift very close to 
those found for cis-[{Pt(PTA)2}2(μ-Cl)(μ-MBTT-κN7,N7′)]Cl (S-CH2-S = 35.85 
ppm; C8 = 150.52 ppm) [7b] and trans-[{PdCl(PPh3)2}2(μ-MBTT-kN7,N7′)] (S-
CH2-S = 36.90 ppm; C8 = 150.30 ppm) [13c] and published MBTT-Cp-PTA 
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ruthenium complexes [{RuCp(PPh3)(PTA)}2-μ-(MBTT-kS7,S′7)] (S-CH2-S = 
33.95 ppm; C8 = 151.85 ppm) [9], [{RuCp(PTA)2}2-μ-(MBTT-kS7,S′7)] (S-CH2-
S = 38.07 ppm; C8 = 153.83 ppm) [9] and [{RuCp(PPh3)(mPTA)}2-μ-(MBTT-
kS7,S′7)] (S-CH2-S = 35.53 ppm; C8 = 151.12 ppm) [10]. While in 2 the 
S(CH2)2S and C8 signals (S-(CH2)2-S = 32.35 ppm; C8 = 151.78 ppm) are 
similar to those for free EBTTH2 (S-(CH2)2-S = 32.00 ppm; C8 = 148.10 ppm) 
and the reported complexes [{RuCp(PPh3)(PTA)}2-μ-(EBTT-kS7,S′7)] (S-
(CH2)2-S = 32.38 ppm; C8 = 150.6 ppm) [9], [{RuCp(PTA)2}2-μ-(EBTT-
kS7,S′7)] (S-(CH2)2-S = 34.74 ppm; C8 = 151.68 ppm) [9], 
[{RuCp(PPh3)(mPTA)}2-μ-(EBTT-kS7,S′7)] (S-CH2)2-S = 32.21 ppm; C8 = 
151.67 ppm) [10]., cis-[{Pt(PTA)2}2(μ-Cl)(μ-N,N-EBTT)]Cl (S-(CH2)2-S = 35.85 
ppm; C8 = 150.52 ppm) [7b] and trans-[{PdCl(PPh3)2}2(μ-EBTT-kN7,N′7)] (S-
(CH2)2-S = 32.70 ppm; C8 = 150.90 ppm) [13c]. Complex 3 displays a similar 
13C{1H} NMR spectrum to those ruthenium complexes with PBTT and mPTA 
ligands previously published. The chemical shifts of the bridging CH2 and C8 
carbons in 3 (-CH2- = 30.05 ppm; C8 = 153.64 ppm) are similar to those for 
[{RuCp(PTA)2}2-μ-(PBTT-kS7,S′7)] (-CH2- = 28.30 ppm; S-CH2- = 30.51 ppm; 
C8 = 149.73 ppm) [{RuCp(PPh3)(PTA)}2-μ-(PBTT-kS7,S′7)] (-CH2- = 30.23 
ppm; C8 = 152.06 ppm) [9], [{RuCp(PTA)2}2-μ-(PBTT-kS7,S′7)] (-CH2- = 28.30 
pp; C8 = 149.73 ppm) [9] and [{RuCp(PPh3)(mPTA)}2-μ-(PBTT-kS7,S′7 (-CH2- 
= 29.73 ppm; S-CH2- = 30.52 ppm; C8 = 148.91 ppm) [10]., but those signals 
for SCH2 in the complexes [{RuCp(PPh3)(PTA)}2-μ-(PBTT-kS7,S′7)] (44.11 
ppm) [9]  and [{RuCp(PTA)2}2-μ-(PBTT-kS7,S′7)] (45.87 ppm) [9] display quite 
different chemical shifts than S-CH2- of 3 (30.51 ppm). Nevertheless, the 
propyl protons display a comparable chemical shift to those in 3, PBTTH2 (-
CH2- = 29.20 ppm; S-CH2- = 30.20 ppm; C8 = 148.20 ppm) and in the 
reported complexes cis-[{Pt(PTA)2}2(μ-Cl)(μ-PBTT-kN7,N′7)]Cl (-CH2- = 32.00 
ppm; S-CH2- = 32.20 ppm; C8 = 151.86 ppm) [7b] and trans-
[{PdCl(PPh3)2}2(μ-PBTT-kN7,N′7)] (-CH2- = 28.60 ppm; S-CH2- = 30.40 ppm; 
C8 = 151.00 ppm) [13c]. The solubility of three complexes in available 
solvents were not enough for a clear observation of CF3SO3- signals. The 
presence in solution of non-coordinated triflate anions was supported by the 
presence of a unique singlet at ca. -78.90 ppm in their 19F NMR. 
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Unfortunately it was not possible to obtain crystals good enough for 
determining the crystal structure of these complexes by single X-ray 
diffraction after numerous attempts. However, the spectroscopic evidence 
supports that the most probable structures for 1, 2 and 3 are those displayed 
in Scheme 1, where each S of the bis-thiotheophylline derivative is bonded to 
a Ru, which completes its coordination geometry with an η5-Cp and two 
mPTA bonded by the P atom. The three complexes were studied by 1H DOSY 
experiments in order to obtain the diffusion diameter of the molecules in water 
that could support the bimetallic nature of them. The obtained value for the 
diffusion constant of 1 (2.62·E-10 m2/s, SI) corresponds to a hydrodynamic 
radius of 9.36 Å [17], which is somewhat bigger than that found for the parent 
bimetallic ruthenium complex [(PTA)2CpRu-μ-CN–RuCp(PTA)2]+ (9.09 Å) [18]. 
Unfortunately the 1H DOSY experiments for complexes 2 and 3 did not 
provided information reliable of the hydrodynamic radius of these complexes, 
which could be produced for a large hydrogen network in solution as indicated 
previously for ruthenium complexes containing PTA derivatives [19].  
The energy of the proposed composition of the complexes was 
calculated by theoretical procedures to obtain a final support for their 
composition. Initially the similar neutral bis-ruthenium molecules containing 
PTA were calculated (Supporting Information) by using previously obtained 
single-crystal X-ray structures [20 ]. The coordinates and energy for the 
calculated structures were included in the Supporting Information.  
The optimized molecular geometries of complexes 1, 2 and 3 are shown in 
Figure 1 and their cartesian coordinates display in Supporting Information. 
The theoretical study showed that in gas phase the kS-complexes containing 
PTA and mPTA display similar stability, being those of mPTA somewhat 
larger than those with PTA (S14, SI). and those found in parent calculated 
complexes [21]. The calculated structures for 1, 2 and 3 kS-complexes are in 
agreement with the X-ray structures of [RuCp(8MTT-kS)(mPTA)2]Cl(CF3SO3) 
[21] although optimized Ru-P and Ru-S bond lengths are larger than 
crystalline ones. Similar deviations were found in bibliography for Ru(II)-
complex structures when calculated at B3LYP/DZVP and B3LYP/LANL2DZ 
levels [22].  
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Figure 1.  B3LYP/3-21G optimized structures of 1, 2 and 3. For the sake of 
clarity hydrogens are not shown. 
 
Selected bond lengths and angles for optimized structures of complexes 1, 
2 and 3 are shown in Table 1. The three complexes show a similar piano stool 
structure in which the purines are basically planar. It is interesting to stress 
that the disposition of the purine with respect to the Cp changes significantly 
from 1 (purine-plane-A/Cp1-plane = 19.32º; purine-plane-B/Cp1-plane = 
71.52º; purine-plane-A/Cp2-plane = 78.36º; purine-plane-B/Cp2-plane  = 
38.44º) to 2 (purine-plane-A/Cp1-plane = 23.61º; purine-plane-B/Cp1-plane = 
62.23º; purine-plane-A/Cp2-plane = 74.59º; purine-plane-B/Cp2-plane  = 
11.08º) and 3 (purine-plane-A/Cp1-plane = 53.76; purine-plane-B/Cp1-plane = 
17.52º; purine-plane-A/Cp2-plane = 78.36º; purine-plane-B/Cp2-plane = 
29.22º). The purine-A and purine-B being that coordinated respectively to Ru1 
and Ru2. 
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Table 1.  Selected Bond Distances (Ǻ) and Angles (deg) for calculated 
structures for 1 (A), 2 (B) and 3 (C). 
 1 2 3 
Ru1 – P1  2.582 2.590 2.54 
Ru1 – P2  2.557 2.580 2.556 
Ru1 – S  2.544 2.524 2.544 
Ru1-Cp(centroid)  1.698 1.697 1.700 
C8t – N7t  1.334 1.334 1.334 
C5t – N7t  1.395 1.394 1.395 
P1 – Ru1 – P2 96.47 96.88 101.81 
P1 – Ru1 – S 86.87 84.77 88.70 
P2 – Ru1 – S 92.72 92.36 92.03 
C8t – S – Ru1 109.47 109.77 109.44 
C5t – S – Ru1 119.19 119.77 110.26 
 
The HOMO orbitals of the complexes (The orbital energies and 
composition in terms of fragments contributions for the most significant 
frontier molecular orbitals are shown in S37, SI) are mainly constituted by the 
8-MBTT-HOMO-orbitals that slightly overlaps through one of the S lobes (1: 4 
%; 2: 5 %; 3: 6 % contribution) with one of the Ru-d orbitals (1: 2 %; 2: 3 %; 3: 
4 % contribution). The LUMO orbitals of 2 and 3 are similar but quite different 
from 1, being the main contribution to the LUMO of 2 and 3 the Ru2 (2: 46 %; 
3: 48 %) orbital and in minor grade the purine, Cp2, mPTA3 and mPTA4 
orbitals. In contrast the main contributions in 1 are both metals (Ru1: 19 %; 
Ru2: 31 %) and there are contributions of all the other molecule groups, being 
the minor that for the phospines (mPTA1:2 %; mPTA2 = 3 %; mPTA3 = 3 %; 
mPTA4 = 3 %). Therefore, the complexes 1, 2 and 3 are similarly stable to the 
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known ruthenium complexes containing mPTA and thiopurines, which also 
justified the preferred coordination through S is drawn from them. 
 
 
3.2. Electrochemistry of 1–3 
 
The redox properties of 1, 2 and 3 in H2O were studied to obtain 
information on the redox behavior of two ruthenium metals bonded to close 
purines in comparison with the previously published bis-ruthenium-8-bis-
thiotheophyllyne complexes. The three complexes exhibited an irreversible 
redox behavior (Figure 2). All the recorded electrode potentials were in a short 
range similar to those found for ruthenium complexes containing Cp and PTA 
[23]. The three oxidation waves for the complexes only can be assigned to 
single-electron charge transfer of two independent Ru centers 
(RuIIRuII/RuIIIRuII and RuIIIRuII/RuIIIRuIII) and therefore, support the proposed 
bimetallic character for the complexes [10,24,25]. It is interesting to stress that 
also for these complexes the oxidation potentials decrease linearly when the 
bispurine-alkyl-bridging group increases in length (Eox(1) = 706 mV (1); 546 
mV (2); 469 mV (3); Eox(2) = 880 mV (1); 826 mV (2); 813 mV (3)). The alkyl 
size and, therefore, the link size between purines have a clear influence on 
the redox properties of the {CpRu(mPTA)2}2+ moiety (Figure 3). There are no 
electronic connections between both metals through the alkyl bridging group 
and through the solvent is also improbable, but clearly there is a net influence 
of the bringing group size between the purines as observed previously in 
parent complexes [{RuCp(PPh3)(PTA)}2-μ-(PBTT-kS7,S′7)], [{RuCp(PTA)2}2-
μ-(PBTT-kS7,S′7)] [9] and [{RuCp(PPh3)(mPTA)}2-μ-(L-kS7,S′7)] [10]. The 
calculated energy difference D(HOMO-LUMO) is in agreement with that 
tendency as it is 3532 eV for 1, 3345 eV for 2 and 3584 eV for 3.  Thus, the 
correlation between the observed redox potentials and the alkyl linking group 
size is correlated with the energy of the orbitals and with the redox properties 
of the complexes. Nevertheless deeper studies and more precise calculations 
should be preformed before to consider that this is a general property of this 
kind of bis-ruthenium-8-bis-thiotheophylline complexes. 
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Figure 2. Cyclic voltammograms in H2O of 1 (red line), 2 (blue line) and 3 
(black line) 
 
 
Figure 3. First and second oxidation potential vs. the numbers of alkyl group 
atoms for 1, 2 and 3. 
 
 
Cell Growth Inhibition.  
The complexes 1-3 have been tested for cell growth inhibition activity 
on the human cancer cell lines cisplatin-sensitive T2 and the cisplatin-
resistant SKOV3 (results reported in Table 2). The growth inhibition activity 
values for cisplatin and the precursors [RuClCp(PPh3)(PTA)] and 
[RuClCp(PTA)2] were also obtained. Each complex was dissolved in DMSO 
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and diluted in AIM-V medium to obtain the final concentrations of 50, 10, and 
2 µM solutions. The percentage of growth inhibition at the three doses for 
each complex allowed us to estimate the IC50, the concentration reducing to 
50% the cell growth of both cell lines. Tests with the cisplatin-sensitive cells 
T2 show that three complexes display a low activity as the precursor 
[RuClCp(PTA)2]). Tests with the cisplatin-resistant SKOV3 cell line showed 
that this complex are similarly active than cisplatin on Pt-resistant cell line. 
This behaviour was previously related to the difficulty for hydrophilic mPTA 
complexes in crossing the lipophilic membranes of the cell and of the nucleus 
to reach the nucleic acids. This suspicion is in agreement with the determined 
partition coefficient Log P for each new complex (Table 2). Those complexes 
(1-3) with negative Log P as found for previously published parent complexes 
[9] do not display significant antiproliferative activity. Therefore, additionally to 
a favourable Log P also should be important to take in account the water 
solubility and the oxidation potential of the complexes. It was evidenced the 
redox capacities of the ruthenium complexes with their redox properties [9], 
the largest is the oxidation potential the higher the anticancer activity. The 
effect of the water solubility is also important but there was not until know any 
study that shows the exclusive effect of the water solubility with the 
antiproliferative activity. 
 
 Table 2. Estimated IC50 on cisplatin sensitive T2 cell line and cisplatin-
resistant SKOV3 of complexes 1-3, Log P, S25,H2O(mg/cm3) and Eo. 
Complex     T2 SKOV3 Log P S25,H2O(mg/cm
3)    Eo (mV) 
1 >50 µM > 50 µM -0.38        30.0       706, 880 
2 > 50 µM > 50 µM -0.49        12.0       546, 826 
3  >50 µM  > 50 µM -0.45        15.0       469, 813 
cis-Pt 2-10 µM > 50 µM    
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4. Conclusion 
The present work details the synthesis of h5-Cp-ruthenium(II) 
complexes bearing the bis(S-8-thiotheophyllinate)methane (MBTTH2), 1,2-
bis(S-8-thiotheophyllinate)ethane (EBTTH2) and 1,3-bis(S-8-
thiotheophyllinate)propane alkane (PBTTH2) and two ligands mPTA. These 
complexes display larger water solubility than those parent bis-thio-
theophylline complexes [{RuCpLL’}2-μ-(Y-kS7,S′7)] (L, L’ = PTA; L = PPh3, L’ 
= PTA, mPTA). The three complexes show two successive one-electron 
oxidations (RuIIRuII/RuIIIRuII and RuIIIRuII/RuIIIRuIII) in agreement with the 
presence of two metals in the molecule. The redox potentials of the 
complexes decrease linearly increasing the bridging alkyl size of the bis(8-
thiotheophylline) ligands that is also the same tendency observed for the 
HOMO-LUMO energy gap, which is probably correlated with the steric 
interaction among the different molecule group. A large theoretical and 
experimental study is needed to finally support that this a general property for 
this kind of complexes. The antiproliferative activities of complexes 1, 2 and 3 
against cisplatin-sensitive T2 and the cisplatin-resistant SKOV3 cancer cells 
were found to be non-relevant in comparison with those for parent 
mononuclear ruthenium complexes, probably due to the reduce solubility of 
this complexes in organic environments as showed by their partition 
coefficient. 
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